Bruton's tyrosine kinase (BTK) inhibitors (BTKi) have been approved by the FDA for the treatment of relapsed/refractory (R/R) MCL; however, intrinsic and acquired BTKi resistance remains a clinically unmet challenge. The gene discussed is BTK; the disease is mantle cell lymphoma.